{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:10:15Z","timestamp":1793693415623,"version":"4.5.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.clinthera.2020.10.002","type":"journal-article","created":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T08:09:36Z","timestamp":1603526976000},"page":"2280-2288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effect of Food on the Pharmacokinetic and Pharmacodynamic Profiles of Hetrombopag in Healthy Volunteers"],"prefix":"10.1016","volume":"42","author":[{"given":"Zhenlei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaogang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.10.002_bib1","first-page":"212","article-title":"Thrombopoietin receptor agonists: eltrombopag and romiplostim for the treatment of chronic immune thrombocytopenia purpura","volume":"23","author":"Atkinson","year":"2019","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.clinthera.2020.10.002_bib2","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s40265-019-01159-0","article-title":"Eltrombopag in immune thrombocytopenia, aplastic anemia, and myelodysplastic syndrome: from megakaryopoiesis to immunomodulation","volume":"79","author":"Fattizzo","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2020.10.002_bib3","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1182\/blood.V97.9.2549","article-title":"Morbidity and mortality in adults with idiopathic thrombocytopenic purpura","volume":"97","author":"Portielje","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2020.10.002_bib4","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.10.002_bib5","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1182\/blood.V95.8.2514","article-title":"Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers","volume":"95","author":"Harker","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2020.10.002_bib6","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1111\/jcmm.13809","article-title":"Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist","volume":"22","author":"Xie","year":"2018","journal-title":"J\u00a0Cel Mol Med"},{"key":"10.1016\/j.clinthera.2020.10.002_bib7","first-page":"221","article-title":"Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopenia","volume":"1","author":"Profit","year":"2006","journal-title":"Core Evid"},{"key":"10.1016\/j.clinthera.2020.10.002_bib8","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/bcpt.12815","article-title":"Safety, pharmacokinetics and pharmacodynamics of hetrombopag olamine, a novel TPO-R agonist, in healthy individuals","volume":"121","author":"Zheng","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2020.10.002_bib9","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s11095-014-1594-x","article-title":"Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection","volume":"32","author":"Zhang","year":"2015","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinthera.2020.10.002_bib10","doi-asserted-by":"crossref","first-page":"E27","DOI":"10.1208\/ps040427","article-title":"Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis","volume":"4","author":"W\u00e4hlby","year":"2002","journal-title":"AAPS PharmSci"},{"key":"10.1016\/j.clinthera.2020.10.002_bib11","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s40262-019-00770-4","article-title":"Pharmacokinetic\/pharmacodynamic modelling and simulation of lusutrombopag, a novel thrombopoietin receptor agonist, for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures","volume":"58","author":"Katsube","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2020.10.002_bib12","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/bcp.12244","article-title":"Population pharmacokinetic\/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease","volume":"77","author":"Farrell","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2020.10.002_bib13","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00280-013-2150-9","article-title":"Population PK\/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia","volume":"71","author":"Hayes","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2020.10.002_bib14","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1177\/0091270010383019","article-title":"Population PK\/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing","volume":"51","author":"Hayes","year":"2011","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2020.10.002_bib15","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.clinthera.2015.03.024","article-title":"Population pharmacokinetic and pharmacodynamic modeling and effects on platelet counts of different dosages of eltrombopag in Chinese patients with chronic primary immune thrombocytopenia","volume":"37","author":"Wu","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2020.10.002_bib16","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1592\/phco.27.7.963","article-title":"Effect of an aluminum- and magnesium-containing antacid on the bioavailability of garenoxacin in healthy volunteers","volume":"27","author":"Krishna","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2020.10.002_bib17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00003088-200140001-00006","article-title":"Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers","volume":"40","author":"Stass","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2020.10.002_bib18","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.clinthera.2012.01.011","volume":"34","author":"Wire","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2020.10.002_bib19","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2009.04.010","article-title":"Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies","volume":"31","author":"Williams","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2020.10.002_bib20","first-page":"R1","article-title":"Noncompartmental vs. compartmental analysis: some bases for choice","volume":"243","author":"DiStefano","year":"1982","journal-title":"Am J Physiol"},{"key":"10.1016\/j.clinthera.2020.10.002_bib21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.clinthera.2020.10.002_bib22","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1177\/0091270010375427","article-title":"Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura","volume":"51","author":"Gibiansky","year":"2011","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2020.10.002_bib23","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/bcp.14259","article-title":"Effect of postdose fasting duration on hetrombopag olamine pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"86","author":"Yang","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2020.10.002_bib24","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1083\/jcb.201304054","article-title":"The incredible journey: from megakaryocyte development to platelet formation","volume":"201","author":"Machlus","year":"2013","journal-title":"J\u00a0Cel Biol"},{"key":"10.1016\/j.clinthera.2020.10.002_bib25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2125.2011.04108.x","article-title":"Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV","volume":"73","author":"Landersdorfer","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2020.10.002_bib26","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1177\/0091270009356444","article-title":"Impact of target-mediated drug disposition on linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients","volume":"50","author":"Retlich","year":"2010","journal-title":"J\u00a0Clin Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820304690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820304690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:53:21Z","timestamp":1758963201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820304690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0149291820304690"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.10.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Food on the Pharmacokinetic and Pharmacodynamic Profiles of Hetrombopag in Healthy Volunteers","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}